Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer-Reference-Cited by-同舟云学术

Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer

Published:2014-11-06 Issue:6 Volume:121 Page:883-892
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Doebele Robert C.¹,Spigel David²,Tehfe Mustapha³,Thomas Sachdev⁴,Reck Martin⁵,Verma Sunil⁶,Eakle Janice⁷,Bustin Frederique⁸,Goldschmidt Jerome⁹,Cao Dachuang¹⁰,Alexandris Ekaterine¹¹,Yurasov Sergey¹²,Camidge D. Ross¹,Bonomi Philip¹³

Affiliation:

1. University of Colorado Anschutz Medical Campus; Aurora Colorado

2. Sarah Cannon Research Institute; Nashville Tennessee

3. University of Montreal Hospital Centre; Montreal Canada

4. Oncology Hematology Associates of Central Illinois; Peoria Illinois

5. Department of Thoracic Oncology, Lung Clinic Grosshansdorf; German Center for Lung Research; Grosshansdorf Germany

6. Sunnybrook Odette Cancer Centre; Toronto Canada

7. Florida Cancer Specialists; Fort Myers Florida

8. Citadelle Regional Hospital Center; Liege Belgium

9. Oncology and Hematology Associates of Southwest VA, Incorporated; Christianburg Virginia

10. Eli Lilly and Company; Indianapolis Indiana

11. Eli Lilly and Company; Bridgewater New Jersey